Benzinga | May 25, 2021 07:04AM EDT

Jefferies Initiates Coverage On Werewolf Therapeutics with Buy Rating, Announces Price Target of $22

Jefferies analyst Chris Howerton initiates coverage on Werewolf Therapeutics (NASDAQ:HOWL) with a Buy rating and announces Price Target of $22.